| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -3.8 | -3.4 |
| EPS (diluted, $ a share) | $-0.64 | $-1.16 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: IMNN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Imunon, Inc.: key numbers
- Share price
- $0.5940Close, Nov 16
- Market cap
- $3.85M
- Shares outstanding
- 6.49MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Imunon, Inc.
All →Imunon Financial Results
Imunon, Inc. reported financial results for the third quarter ended September 30, 2026, and provided updates on its lead clinical candidate IMNN-001 for advanced ovarian cancer. The company highlighted its Phase 3 OVATION 3 study and a recent Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to support further development of IMNN-001.
“IMUNON continues to make significant progress in the clinical development of IMNN-001 for advanced ovarian cancer. The data generated to date, our collaboration with the National Cancer Institute, and the favorable safety profile observed across studies support the ongoing advancement of the program and its potential to provide a transformative treatment for women with this difficult disease.”
Stacy R. Lindborg, Ph.D., President and Chief Executive Officer
“We have also taken steps to continue to sharpen our strategic focus and strengthen IMUNON’s financial position. Through our agreement to transition ThermoDox® to a dedicated development partner and our recent debt-for-equity exchange, we are demonstrating the disciplined approach to capital allocation that we believe is essential to advancing our most significant clinical opportunity while preserving opportunities for future value creation.”
Stacy R. Lindborg, Ph.D., President and Chief Executive Officer
Imunon Investor Presentation
Imunon, Inc. has released an updated investor presentation for October 2026. The company intends to use this deck for upcoming investor calls and conferences to discuss its strategic initiatives and business operations.
Imunon Divestiture to VoxelDox Therapeutics, Inc. for $16.5M
Imunon entered into an asset purchase agreement to sell its ThermoDox assets to VoxelDox Therapeutics, which intends to develop the drug for glioblastoma. Imunon will receive a 4.76% equity stake in VoxelDox, up to $16.5 million in clinical and regulatory milestone payments, and royalties on future net sales. The closing is contingent on VoxelDox raising at least $2.5 million in financing.
- Value
- $16.5M
- Counterparty
- VoxelDox Therapeutics, Inc.
Imunon $1.2M Debt Financing with Streeterville Capital, LLC
Imunon, Inc. entered into an exchange agreement with Streeterville Capital, LLC to exchange $1.2 million of the principal amount of an existing Secured Promissory Note (A-1 Note) for 120 shares of newly designated Series B Preferred Stock. This transaction reduces the company's outstanding debt obligations under the A-1 Note by the amount exchanged, while the Series B Preferred Stock will carry an 8% annual return and a stated value of $12,000 per share.
- Value
- $1.2M
- Counterparty
- Streeterville Capital, LLC